We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Rejects Watson Bioequivalency Claims to Block Generic Rapaflo
FDA Rejects Watson Bioequivalency Claims to Block Generic Rapaflo
October 23, 2013
The FDA has categorically turned down Watson Pharmaceuticals’ attempt to block Sandoz from producing a generic version of its prostate drug Rapaflo (silodosin).